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Abstract
Photoacoustic tomography (PAT) also referred to as optoacoustic tomography (OAT) is a hybrid
imaging modality that employs nonionizing optical radiation and ultrasonic detection. Here, we
describe the application of a new class of optical contrast agents based on mesoscopic hollow gold
nanospheres (HAuNS) to PAT. HAuNS are ~40 nm in diameter with a hollow interior and consist
of a thin gold wall. They display strong resonance absorption tuned to the near infrared (NIR) range,
with an absorption peak at 800 nm, whose photoacoustic efficiency is significantly greater than that
of blood. Following surface conjugation with thiolated poly(ethylene glycol), the pegylated HAuNS
(PEG-HAuNS) had distribution and elimination half-lives of 1.38±0.38 and 71.82±30.46 h,
respectively. Compared with PAT images based on the intrinsic optical contrast in nude mice, the
PAT images acquired within 2 h after intravenous administration of PEG-HAuNS showed the brain
vasculature with greater clarity and detail. The image depicted brain blood vessels as small as ~100
µm in diameter using PEG-HAuNS as contrast agents. Preliminary results showed no acute toxicity
to the liver, spleen, or kidneys in mice following a single imaging dose of PEG-HAuNS. Our results
indicate that PEG-HAuNS are promising contrast agents for PAT, with high spatial resolution and
enhanced sensitivity.
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1. Introduction
Noninvasive molecular and functional imaging techniques show promise for detecting and
monitoring various physiological and pathological conditions in animals and, ultimately,
© 2009 Elsevier Ltd. All rights reserved.
*Corresponding author: Department of Experimental Diagnostic Imaging, Unit 59, The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Boulevard, Houston, Texas 77030. Phone: (713) 792-5182. Fax: (713) 794-5456. cli@mdanderson.org.
#Present address: Grodno State University, Grodno, Belarus
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Biomaterials. Author manuscript; available in PMC 2011 March 1.
Published in final edited form as:
Biomaterials. 2010 March ; 31(9): 2617. doi:10.1016/j.biomaterials.2009.12.007.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
humans. Among these imaging modalities, photoacoustic imaging offers higher spatial
resolution and allows deeper tissues to be imaged than most optical imaging techniques [1–
8]. Photoacoustic tomography (PAT) referred to as optoacoustic tomography (OAT) is a
hybrid, nonionizing imaging modality that combines the merits of both optical and ultrasonic
imaging methods [6]. PAT detects absorbed photons ultrasonically through the photoacoustic
effect: a short-pulsed laser irradiates biological tissues and induces wideband ultrasonic waves
(photoacoustic waves) as a result of transient thermoelastic expansion [8]. Owing to the optical
absorption of hemoglobin, PAT has been successfully applied to the visualization of different
structures in biological tissues, especially to imaging of the cerebral cortex in small animals
[9,10], human blood vessels [10,11], microvasculature of tumors [4,12] and quantifying
oxygen hemoglobin saturation in tumors [2,5,9,13].
PAT is capable of monitoring exogenous optical contrast agents with high sensitivity and
specificity [5,11,14]. Optical contrast allowed spectroscopic separation of signal contributions
from multiple optical absorbers such as oxyhemoglobin, deoxyhemoglobin, and molecular
contrast agents, thus enabling simultaneous molecular and functional imaging [5]. Recently,
gold nanoparticles such as gold nanoshells [7], nanocages [15,16], nanorods [17–23], and
nanobeacons [24], as well as carbon nanotubes [25–27], have been employed as molecular
contrast enhancement agents in the near-infrared (NIR) range, where intrinsic optical
absorption in tissue is minimal and penetration is optimal [28]. These gold nanoparticles can
generate greater photoacoustic signals due to light excitation in the NIR spectral region, where
the signal ratio of gold nanoparticles to hemoglobin is higher, thus showing greater contrast to
endogenous chromophores [14,26]. Moreover, the gold nanoparticles are not susceptible to
photobleaching, a problem commonly associated with the use of organic dyes. These
nanoparticles showed enhanced photoacoustic mapping of cerebral vasculature [7,15], sentinel
lymph node [16,18,27] and tumor in vivo [25,26], joint tissue ex vivo [29], and macrophages
in atherosclerotic plaques [30]. PAT also can noninvasively image the progressive
extravasation of gold nanoshells through solid tumor vasculature in vivo [31]. In addition,
gadolinium (Gd)-doped, gold-speckled silica nanoparticles were synthesized as multimodal
nanoparticulate contrast agents for noninvasive imaging using both magnetic resonance
imaging (MRI) and PAT [32].
Hollow gold nanospheres (HAuNS) have the unique combination of small size (outer diameter,
40–50 nm), spherical shape, and a hollow interior that results from their highly uniform
structure [33–35]. The HAuNS have a strong and precisely tunable absorption band peaked at
~800 nm and are coated with polyethylene glycol (PEG, MW 5000) to increase their blood
circulation half-life. The purpose of this study was to evaluate the use of these HAuNS as a
new molecular contrast agent for PAT. The accuracy of PAT with pegylated HAuNS (PEG-
HAuNS) of mouse brain vasculature was confirmed through histological analysis. The
pharmacokinetics, biodistribution, and acute toxicity of PEG-HAuNS were assessed to provide
preliminary data for future translation in clinical applications.
2. Materials and Methods
2.1. Materials
Biotinylated secondary antibody, straptavidin-horseradish peroxidase (straptavidin-HRP),
3,3’-diaminobensidine (DAB), hematoxylin, luciferin, and 4% paraformaldehyde were
purchased from Fisher Scientific (Waltham, MA). Rat anti-mouse CD31 monoclonal antibody
was purchased from Millipore (Billerica, MA). Alexa Fluor 594-tagged goat anti-rat IgG and
RPMI-1640 phenol red free cell culture medium were purchased from Invitrogen (Carlsbad,
CA). Rat anti-mouse CD 68 antibody was obtained from AbD Serotec (Raleigh, NC).
Isoflurane was obtained from Baxter (Deerfield, IL). Methoxy-polyethylene glycol-SH
(MPEG-SH, MW=5,000), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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(MTT)-based in vitro toxicity assay kit, 10% buffered formalin-saline, and all the other solvents
were purchased from Sigma-Aldrich Chemical (St. Louis, MO). 111InCl3 was purchased from
Perkin-Elmer (Waltham, MA). All the chemicals and solvents were at least ACS grade and
were used without further purification. Human umbilical vein endothelial cells (HUVECs)
were obtained from the American Type Culture Collection (Manassas, VA).
2.2. Synthesis of PEG-HAuNS
HAuNS were synthesized according to our previously published methods [33,34]. For the
conjugating reaction, about 0.5 mg of MPEG-SH was added into the HAuNS solution
(8.5×1012 nanoparticles in 4.0 mL water). The solution was stirred overnight at room
temperature and then centrifuged at 7000 rpm for 15 min. The PEG-HAuNS were washed three
times with water and collected for further characterization.
2.3. Calculation of Extinction Spectra of PEG-HAuNS
In the case of metallic nanoshells, when the real part of a dielectric permittivity of a nanoshell
has a negative value, the spectra of optical absorption and scattering have specific resonance
peaks, which correspond to the excitation of surface plasmons in nanoshells [36]. To calculate
these spectra of absorption and scattering of light in a gold nanoshell with a water core, we
assumed that the incident light was a plane wave propagating along the z axis of a Cartesian
system of coordinates. This assumption allowed us to apply standard Mie theory [37] to our
calculations, as well as to use the following expressions for absorption (σabs) and scattering
(σscat) cross-sections [38]:
(1)
where  is a dielectric constant of a host medium, km is a wave number of an incident plane
wave (in a host medium), and an, bn are the Mie coefficients of scattered field. It should be
noted here that in the cross-sections of Eq. (1), the physical meaning of absorbed and scattered
power was divided by the energy density of the incident laser radiation in a vacuum. To
calculate the Mie coefficients, we used boundary conditions for the Maxwell equations for the
considered geometry. In the case of a metal nanoshell with a dielectric core, the Mie coefficients
were calculated by using the method described by Kerker [39].
To quantify the photoacoustic contrast enhancement by PEG-HAuNS, a three-dimensional
tomographic image was obtained from a quantitatively characterized phantom using a
photoacoustic tomography system (Fairway Medical Technologies, Houston, TX). The
phantom was made of poly(vinyl-chloride) plastisol (PVCP) with added TiO2 powder for
optical scattering and contained 4 embedded tubes with diameter of 0.6 mm filled with 4
different optically absorbing media: aqueous solution of CuSO4 (OD=2.0), mouse blood
(OD=1.6), aqueous solution of India ink (OD=0.8) and water suspension of PEG-HAuNS
(OD=0.7). The optical density (OD) per 1 cm distance in each medium was determined using
a Vis/NIR spectrophotometer (DU 800, Beckman, CA). The phantom was illuminated with
300 ns long pulses of an Alexandrite laser operating at the wavelength of 755 nm. The optical
fluence incident the phantom surface was approximately 10 mJ/cm2, so that the effective optical
fluence incident the tubes was about 1 mJ/cm2. The image brightness in the location of each
tube was measured.
Lu et al. Page 3
Biomaterials. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.4. PAT Experimental Setup
The setup for PAT of the mouse brain was made in accordance with previous reports [7,15].
A Q-switched Nd:YAG laser (LS-2137/2, LOTIS TII, Minsk, Belarus) and pumped tunable
Ti:sapphire laser (LT-2211A, LOTIS TII, Minsk, Belarus) were employed to excite
photoacoustic signals. The lasers provided a pulse duration of less than 15 ns, pulse repetition
rate of 10 Hz, and wavelength of 800 nm. The incident energy density of the laser beam was
controlled to be less than 10 mJ/cm2 on the surface of the mouse head. An unfocused ultrasonic
transducer (V323, 63.5 mm in diameter; Panametrics, Waltham, MA) with a central frequency
of 2.25 MHz and a −6 dB bandwidth of about 70% was used to detect the ultrasound signals.
Male nude mice (8–10 weeks old; Charles River Laboratories, Wilmington, MA) were used
for the imaging experiments. All animal studies (n=3) were carried out in accordance with
institutional guidelines. The mice were anesthetized through the inhalation of a mixture of
O2 and isoflourane during the whole experiment. The mouse was set on a homemade mount
so that its head protruded into the water tank filled with water through a hole in the tank’s
bottom. The hole was sealed with a piece of polyethylene film, and the head of the mouse was
in direct contact with the film but not with water in the tank. Ultrasonic coupling gel was applied
to the surface of the mouse’s head. The photoacoustic signals detected by the ultrasonic
transducer were amplified (5072PR; Olympus, Waltham, MA) and then recorded by a data
acquisition card (Compuscope 14200; Gage Applied, Lockport, IL) installed in the computer
(Precision PWS 490; Dell, Round Rock, TX). The photoacoustic images were reconstructed
through a modified back-projection algorithm [40].
One PAT scan was performed before the injection of the contrast agent. Afterwards, PEG-
HAuNS (about 2.5×1011) were injected into the mouse tail vein. PAT scanning started at 5,
15, 30, 60, 90, and 120 min, respectively, after dosing. After data acquisition, the mice were
sacrificed using CO2. Open-skull surgery was performed to photograph the cerebral cortex.
The mouse brain was embedded in Tissue Tek O.C.T. compound® (Sakura, Torrance, CA)
for frozen sectioning, and immunofluorescence staining was performed on brain tissue slices.
2.5. Immunofluorescence Analysis
The mouse brain frozen sections were fixed with 4% paraformaldehyde for 15 min at room
temperature. After being washed with PBS, the slices were incubated with 10% goat serum for
30 min at 37°C and then subjected to rat anti-mouse CD31 monoclonal antibody (1:100) at 4°
C overnight. Alexa Fluor 594-tagged goat anti-rat IgG (1:750) was applied as the secondary
antibody for 1 h at room temperature. The slices were examined by fluorescence microscopy
(Zeiss Axio Observer.Z1, Carl Zeiss MicroImaging GmbH, Göttingen, Germany). HAuNS
nanoparticles were detected on the basis of their light scattering under the dark field.
2.6. Pharmacokinetics and Biodistribution Study
A chelation agent, S-2-(4-[5-(1,2)dithiolane-3-pentanamide]benzyl)-diethylenetriamine
pentaacetic acid (DTPA-TA), was synthesized and conjugated to the surface of HAuNS
according to previous reported procedures [34,41]. Briefly, for conjugation of the radiometal
chelator to the nanoparticles, DTPA-TA (1 mg/mL, 10 µL) was mixed with a 1-mL aqueous
solution of HAuNS (1×1013 particles/mL) for 4 h at room temperature. This was followed by
conjugation of PEG-SH to the nanoparticles according to the above described procedures. For
radiolabeling, aliquots of PEG-HAuNS(DTPA) (1×1013 particles/mL, 0.5 mL) in 0.1 M
sodium acetate solution (pH 5.5) were mixed with an aqueous solution of 111InCl3 (~1 mCi)
for 30 min. The radiolabeled HAuNS was then purified by centrifugation at 8,000 rpm for 5
min and washed three times with PBS. The radiolabeling efficiency was >99%, and
radiolabeled nanoparticles were stable in full mouse serum [34].
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For pharmacokinetic analysis, seven nude mice were intravenously injected with 111In-labeled
PEG-HAuNS (~50 µCi/mouse), and blood samples were collected from the tail vein at
predetermined time points. The animals were euthanized by CO2 exposure at the end of the
study. For the biodistribution study, 14 mice were given the same amount of radiolabeled PEG-
HAuNS (~50 µCi/mouse). The mice were divided into two groups (n=7) and sacrificed after
24 h and 168 h (7 days), respectively. The blood, heart, liver, spleen, kidney, lung, stomach,
intestine, muscle, bone, and brain were removed and weighed, and radioactivity was measured
with a Cobra gamma counter (Packard, Downers Grove, IL). Uptake of 111In-labeled
nanoparticles in various organs was calculated as percentage of injected dose per gram of tissue
(%ID/g).
2.7. Cytotoxicity Assay
The cytotoxicity of PEG-HAuNS was evaluated in HUVECs according to a previously reported
method [42]. Following three days of continuous exposure to the nanoparticles, cell viability
was measured using an MTT-based in vitro toxicology assay kit. The absorbance was measured
on a SpectraMax Plus384 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA),
with a test wavelength of 570 nm and a reference wavelength of 630 nm. The percentage of
viable cells at each concentration relative to nontreated cells was plotted. Citrate-stabilized
gold nanoparticles (AuNP) and cetyltrimethylammonium bromide (CTAB) stable gold
nanorods with a particle size of around 40 nm were synthesized according to previous reports
and used as controls [42].
In a separate experiment, the intensity of bioluminescence produced by human glioblastoma
U87 cells stably transfected with the luciferase gene (U87-TGL, a gift from Dr. Juri Gelovani,
The University of Texas M. D. Anderson Cancer Center) was measured to evaluate the
cytotoxicity of the nanoparticles. The cells were seeded onto a 96-well plate. After three days’
exposure to different concentrations of the above particles, the cells were subjected to luciferin
(0.5 mg/ml) in RPMI-1640 phenol red free. The bioluminescent signals were recorded using
the Xenogen IVIS-200 Optical In Vivo Imaging System (Caliper Life Sciences, Hopkinton,
MA). The luminescent intensity was quantified, and the percentage of the intensity at each
concentration relative to that of the nontreated cells was plotted.
2.8. Blood hematology, Biochemistry and Histology
Fourteen male Swiss mice were randomly divided into two groups (n=7). Each group received
an intravenous injection of 2.5×1011 PEG-HAuNS or saline. Blood samples were collected on
7 days after nanoparticle injection for hematologic and chemical analysis.
For histological evaluation, portions of the kidney, liver, and spleen collected on day 7 after
PEG-HAuNS injection were fixed in 10% buffered formalin-saline at 4°C overnight and then
embedded in paraffin blocks. Tissue sections 5 µm thick were stained with hematoxylin and
eosin (H&E). Immunohistochemical analysis was performed using a 1:100 dilution of rat anti-
mouse CD68 antibody overnight at 4°C. Slides were then rinsed and incubated with
biotinylated secondary antibody, after which they were incubated with straptavidin-HRP.
Slides were developed with DAB and counter-stained with hematoxylin.
2.9. Statistical Analysis
The blood pharmacokinetic parameters of the radiotracer were analyzed with a two-
compartmental model using WinNonlin 5.0.1 software (Pharsight Corporation, Palo Alto, CA).
Student’s t-test (two tailed, unpaired) was performed to compare serum analysis results
between nanoparticle groups and saline controls, and p values less than 0.05 were considered
statistically significant.
Lu et al. Page 5
Biomaterials. Author manuscript; available in PMC 2011 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Results and Discussion
3.1. PEG-HAuNS Characterizations
A transmission electron microscopy (TEM) image of PEG-HAuNS shows that the
nanoparticles had a mean outer diameter of 43 to 46 nm and a mean shell thickness of 2 to 4
nm (Fig. 1A). The resonance absorbance of these nanoparticles was tuned to peak at 800 nm
(Fig. 1B). The optical absorption and scattering coefficients of gold nanospheres (i.e.,
absorption and scattering cross-sections per unit volume) were calculated (Fig. 1C). Our
calculations showed that HAuNS with an outer diameter of 45 nm and shell thickness of 2.5
nm had an extinction spectrum that peaked at 800 nm. The theoretical dimensions of HAuNS
matched well with the measured dimensions shown in the TEM image (Fig. 1A). This result
validates our calculation, and provides a valuable theoretical approach towards designing
HAuNS with absorption and scattering peaks at predetermined wavelengths in the NIR region.
According to the Mie theory and the plasmon resonance theory, the optical absorption
coefficient of gold nanoshells increases, while the optical scattering coefficient decreases, with
decreasing diameter of the core. The peak wavelength experiences a red shift with decreasing
shell thickness. Although the larger size of previously reported silica-cored gold nanoshells
(145-nm outer diameter, 10-nm shell thickness) resulted in a much greater extinction value,
the extinction of these gold nanoshells was dominated by scattering [15]. The absorption
coefficient of the silica-cored gold nanoshells was calculated as 16.9 µm−1, according to its
absorption cross-section of 0.027 µm2 [15]. In contrast, the extinction of our HAuNS was
dominated by absorption, owing to their smaller size (Fig. 1C). At 800 nm, the absorption
coefficient of HAuNS reached ~540 µm−1, which is 32 times as high as that of silica-cored
gold nanoshells. However, the scattering coefficient of HAuNS (~78 µm−1) is similar as that
of silica-cored gold nanoshells (~75 µm−1 calculated from the scattering cross-section of 0.12
µm2 [15]). Since PAT is an absorption-based technique, this high absorption coefficient makes
our HAuNS an excellent contrast agent for photoacoustic imaging.
To demonstrate utility of PEG-HAuNS as a photoacoustic contrast agent, we acquired a
tomographic image of a tissue mimicking phantom made of PVCP with embedded four tubes
filled with optically absorbing liquid media (Fig. 1D). The long duration of the laser pulses
used in this experiment limited the image resolution to about 1 mm. Thus, the tubes with internal
diameters of 0.6 mm are visualized in Fig. 1D as tubes with larger diameters. The diameter of
each tube on the image increased with the object brightness (Fig. 1E). The distribution of the
photoacoustic image brightness through the cross-section of each tube is shown by bell-shaped
curves. Analysis of the image brightness revealed that the photoacoustic image of PEG-HAuNS
was brighter than that of whole blood, aqueous solutions of CuSO4 and India ink. Even though
blood had optical density 2.3-fold greater than that of PEG-HAuNS in water suspension, the
photoacoustic brightness of PEG-HAuNS was 2.5-fold greater than that of blood. This
experiment demonstrates that the photoacoustic efficiency of PEG-HAuNS is significantly
greater than that of blood.
3.2. Mapping of Mouse Brain Vasculature
PAT images of the cerebral cortex of a mouse before and after a single injection of PEG-
HAuNS are presented in Figure 2. Because of the low intrinsic absorption of oxyhemoglobin
and deoxyhemoglobin at 800 nm, the photoacoustic signal was weak, with a low signal-to-
noise ratio that showed only large vessels distributed along the mouse brain cortical surface,
such as the middle cerebral artery (Fig. 2A, arrow). However, 5 min after the injection of PEG-
HAuNS, the PAT image revealed the brain vasculature with much greater clarity, especially
small blood vessels (Fig. 2B). This enhanced clarity was attributed to the strong photoacoustic
signal generated with PEG-HAuNS. The circulating PEG-HAuNS enhanced the contrast
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between the blood vessels and the brain parenchyma. This is better appreciated in a differential
image (Fig. 2D) obtained by subtracting the preinjection image (Fig. 2A) from the postinjection
image pixel by pixel (Fig. 2B). At 2 h post-injection, the photoacoustic images remained
essentially unchanged, indicating significant amount of PEG-HAuNS circulating in the blood
(Fig. 2C and 2E). The PAT images of the mouse brain matched well with the open-skull
anatomical photograph (Fig. 2F).
At higher magnification, PAT revealed not only the structure of large vessels (Fig. 3A, yellow-
framed picture) but also small blood vessels (Fig. 3A, green-framed pictures) 2 h after PEG-
HAuNS injection. Indeed, brain blood vessels in the superficial cortex as small as ~100 µm in
diameter could be clearly seen (Fig. 3A, arrows).
In order to confirm the distribution of PEG-HAuNS in the brain, the blood vessels were stained
with anti-CD31 antibody, while the scattering signal of the gold nanoparticles was detected
under a dark field. As shown in Fig. 3B and 3C, the HAuNS were located on the luminal side
of the blood vessels 2 h after intravenous injection. In brain capillaries, most of the
nanoparticles colocalized or stayed adjacent to the brain capillary endothelial cells (Fig. 3D).
There was no particle extravasation into the brain parenchyma. This was attributed to the blood-
brain barrier, which has been shown to impede the penetration of such particles [7]. Therefore,
our finding proves that the distribution of high-optical-contrast agents in the vasculature can
afford clear and enhanced photoacoustic imaging of brain vessels of live mice with intact skin
and skull, as well as a low brain parenchymal background.
The absorption signals from the PAT images acquired at each time point after injection of PEG-
HAuNS were integrated and normalized to the signal integration of the preinjection image (Fig.
4, n=3). The highest photoacoustic signal was acquired at 5 min after contrast agent injection
and the intensity was 2.3-fold higher than that of the preinjection value. The absorption
enhancement remained high, even after 2 h, with an average increase over the preinjection
value of 1.9-fold. This is in accordance with the contrast enhancement seen on postinjection
PAT images at 5 min and at 2 h (Fig. 2B and 2C).
The molar extinction coefficient associated with the optical absorption cross-section of HAuNS
is calculated to exceed 1.4×1011 M−1·cm−1 at 800 nm based on Fig. 1C. In comparison, the
molar extinction coefficient of hemoglobin is ~1×103 M−1·cm−1 [43]. As a result, only ~20
pM concentration of PEG-HAuNS can give approximately as strong optical absorption as
hemoglobin at the typical concentration of 2.3 mM in blood. This gives one an opportunity to
inject a relatively small volume of highly concentrated PEG-HAuNS in the blood stream of an
animal to enhance the optical absorption of blood in the NIR spectral range. Such enhancement
might be even more prominent for targeted tissues of diagnostic interest such as early malignant
lesions with relatively low blood content.
3.3. Pharmacokinetics and Biodistribution of PEG-HAuNS
Fig. 5A illustrates that the mean blood activity-time profile of 111In-labeled PEG-HAuNS after
i.v. injection fit a two-compartment model, with a distribution half-life of 1.38±0.38 h and an
elimination half-life of 71.82±30.46 h. Other pharmacokinetic parameters of PEG-HAuNS
after intravenous injection are summarized in Table 1. Fig. 5B shows the tissue distribution
of 111In-labeled PEG-HAuNS 1 day and 7 days after injection. The kidneys, liver, and spleen
were the major organs taking up a significant amount of HAuNS. Compared with the amount
of PEG-HAuNS in tissues 1 day after injection, the uptake of PEG-HAuNS in all organs with
the exception of the kidneys and bone significantly decreased at day 7 after injection.
Zhang et al [41] investigated the size-dependent pharmacokinetics of pegylated solid gold
nanoparticles with an average diameter of less than 100 nm. They found that 20-nm and 40-
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nm gold nanoparticles were cleared from the blood more slowly and had less uptake in the
liver and spleen than 80-nm nanoparticles. The reason might be due to the pegylated smaller
particles having higher PEG density than larger particles. The thick PEG layer effectively
insulated the gold particles from nonspecific binding to plasma proteins, resulting in reduced
liver uptake [41]. Our particles with an outer diameter of 45 nm have a similar distribution
half-life to that reported for pegylated solid gold nanoparticles 40 nm in diameter (1.38 h v.s.
1.32 h [41]). However, the blood elimination half-life of PEG-HAuNS is significantly longer
compared to that of pegylated solid gold nanoparticles (71.8 h v.s. 10.1 h [41]). One possible
explanation is the difference in particle density: HAuNS have lower density than solid Au
nanoparticles. Further studies are needed to investigate whether and how particle density may
influence the pharmacokinetics and biodistribution of gold nanoparticles.
3.4. Toxicity Evaluation of PEG-HAuNS
Fig. 6A shows the viability of HUVECs following 3 days of continuous exposure to PEG-
HAuNS, citrate-stabilized AuNP, or CTAB-capped gold nanorods at different concentrations,
as measured by the MTT assay. The PEG-HAuNS and AuNP preparations were not toxic at
concentrations up to 500 µM (gold atoms). In contrast, over 90% of HUVECs were killed when
the cells were incubated with the CTAB-capped gold nanorod solution at a concentration of 5
µM. The cytotoxicity was also evaluated through the measurement of the function of
bioluminescence transformation in human glioblastoma U87 cells stably transfected with the
luciferase gene (U87-TGL). Upon addition of luciferin substrate, the decrease in luminescent
intensity represented the cytotoxic effects of the different nanoparticles on the cells (Fig. 6B
and 6C). The data suggest that PEG-HAuNS are not inherently toxic to human cells because
the HAuNS are made of pure gold and are, therefore, expected to be nontoxic [42]. In
comparison, the structure-directing agent CTAB on the surface of gold nanorods was highly
toxic to the cells at a concentration as low as ~10 nM [44].
We further investigated the in vivo toxicity of PEG-HAuNS in mice. Following i.v. injection
of a single imaging dose of PEG-HAuNS (2.5×1011 particles per mouse), there were no deaths
in any of the experimental animal groups during the study period. There was no significant
difference in any tested serum biochemical parameters between the mice treated with PEG-
HAuNS and those treated with saline 7 days after intravenous injection (Table 2). This indicates
that a single PAT imaging dose of PEG-HAuNS does not impair liver or kidney function. H&E
staining of the liver, spleen, and kidneys did not show any apparent change in cellular structures
7 days after PEG-HAuNS injection (Fig. 7). To evaluate the acute inflammation caused by the
nanoparticles, the tissue sections of liver, spleen, and kidney were stained with CD68, a
monocyte/macrophage-specific marker [45]. Because the nanoparticles were significantly
entrapped in the liver and spleen (Fig. 5B), macrophages in the liver (Kupffer cells) and spleen
were believed to have taken up the majority of the nanoparticles [46,47]. However,
immunohistochemical analysis of hepatic lobules of the liver in mice did not show an increased
amount of Kupffer cells (positive staining) 7 days after PEG-HAuNS dosing compared to saline
controls (Fig. 7). The macrophages in the marginal zone of the spleen did not significantly
increase either. Mesangial cell proliferation with mesangial expansion is commonly observed
in glomerulonephritis [48]. Here, though, we did not see a significant change in the amount of
positively stained mesangial cells (Fig. 7, arrows) in the kidney in mice injected with PEG-
HAuNS compared with saline controls.
It is known that a large portion of intravenously injected nanoparticles are taken up and
eliminated by phagocytes, including monocytes in blood circulation and macrophages in tissue
[46]. If a non-specific immunoresponse takes place, the monocytes will be recruited from the
circulation and infiltrate and develop into macrophages in the inflammatory tissue [45]. Thus,
any acute inflammation caused by nanoparticles in vivo could be characterized by an increase
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in monocytes and macrophages. Previous results have shown that most of the inflammation
following nanoparticle injection occurs in the following regions: the hepatic sinusoid, where
Kupffer cells capture the blood nanoparticles; the splenic marginal zone, where the
nanoparticles are sequestered by macrophages and tightly bound to a reticular meshwork; and
the renal corpuscle, where mesangial cells phagocytize and clear the blood nanoparticles
[45]. In our study, no such inflammatory reactions occurred in these regions, which is consistent
with our in vitro results showing no cytotoxicity against human cell lines. Taken together, our
results show that intravenous administration of a single imaging dose of PEG-HAuNS does
not cause acute toxicity to the liver, spleen, or kidneys in mice. Clearly, further work is needed
to elucidate the dose-response relationship to acute toxicity. Moreover, the long-term toxic
effects of the presence of nanoparticles must be examined before taken into humans.
4. Conclusion
In this study, we evaluated a new nanoparticulate optical contrast agent based on HAuNS for
photoacoustic imaging. The particles can be fabricated with surface Plasmon resonance tunable
at the NIR wavelength (~800 nm), which allows deeper penetration of laser light and lowers
the intrinsic background noise. The photoacoustic efficiency of HAuNS is significantly greater
than that of blood. The pegylated HAuNS showed the mouse brain vasculature with greater
clarity and more detailed structures, with significant contrast enhancement, than PAT imaging
without contrast. Brain blood vessels as small as about 100 µm in diameter could be clearly
seen using our PAT system with PEG-HAuNS. Pharmacokinetic results demonstrate that PEG-
HAuNS has long circulation in the blood pool. Preliminary toxicity results showed no acute
toxicity to the liver, spleen, and kidneys in mice with a single intravenous PAT imaging dose
of PEG-HAuNS. Our results indicate that HAuNS are a promising contrast agent for PAT
imaging techniques, with high spatial resolution and satisfactory sensitivity based on strong
optical absorption in the NIR region. Work on molecular PAT imaging of tumor associated
biomarkers using HAuNS as the imaging probe is under way.
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Figure 1.
(A) TEM image of PEG-HAuNS (Bar=50 nm). The average outer diameter was 45 nm, and
thickness of the shell was 2.5 nm. (B) Experimental absorbance spectrum of PEG-HAuNS in
water, which peaked at 800 nm. (C) Theoretically calculated absorption and scattering spectra
of PEG-HAuNS with water core having dielectric permittivity of 1.77. The inner core radius
was 20 nm and gold shell thickness was 2.5 nm, whose values are consistent with those shown
in TEM. (D) Tomographic image of a tissue mimicking phantom made of poly(vinyl-chloride)
plastisol with embedded four tubes filled with optically absorbing liquid media. (E)
Quantitative analysis of the photoacoustic image brightness through the cross-section of each
tube from (D). The color scale was designed in three steps: from black to blue/green to red.
All tubes with different levels of brightness reflected in the object diameter.
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Figure 2.
Noninvasive PAT imaging of a mouse brain in vivo employing PEG-HAuNS and NIR light at
a wavelength of 800 nm. Photoacoustic image acquired (A) before, (B) 5 min after, and (C) 2
h after the intravenous injection of PEG-HAuNS. (D) and (E) Differential images that were
obtained by subtracting the pre-injection image from the post-injection images (Image D =
Image B − Image A; Image E = Image C − Image A). Arrow, middle cerebral artery. Bar=2
mm. (F) Open-skull photograph of the mouse brain cortex obtained after the data acquisition
for PAT. Bar=2 mm.
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Figure 3.
(A) Enhanced photoacoustic signals revealed clear and detailed structure of large (yellow-
framed picture) and small (green-framed picture) blood vessels in the mouse brain at higher
magnification 2 h after intravenous injection of PEG-HAuNS. Arrows represent the small
blood vessels with a diameter of about 100 µm, which can be seen in the contrast-enhanced
images. (B–D) Distribution of PEG-HAuNS in brain vessels 2 h after injection (Bar=10 µm).
Brain vessels were stained with anti-CD31 antibody (red fluorescence), while the scattering
signals of gold particles were detected under a dark field (pseudo-green). Z-stack images
showed the particles located on the luminal side of brain blood vessels (B and C). In brain
capillaries, three-dimensional reconstruction images show that the particles colocalized or
stayed adjacent to the brain capillary endothelial cells (D).
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Figure 4.
The integrated absorption calculated from the in vivo brain images of three mice at different
times following the injection of PEG-HAuNS. The presented values were normalized to that
of the integrated absorption of the image obtained before the injection.
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Figure 5.
(A) Blood activity-time profile of PEG-HAuNS(DTPA-111In). The closed circles represent the
mean radioactivity expressed as a percentage of the injected dose per gram of blood from seven
mice. Data are expressed as mean ± SD. (B) Biodistribution of PEG-HAuNS(DTPA-111In) in
nude mice 1 and 7 days after injection. Data were plotted as percentage of injected dose per
gram of tissue (% ID/g). Mean ± SD (n = 7). *, p<0.05; **, p<0.01.
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Figure 6.
(A) Viability of HUVEC cells exposed to different nanoparticles. Cell viability was measured
by the MTT assay. The data were plotted as the percentage of viable cells compared to untreated
controls. (B) Cell viability of U87-TGL cells stably transfected with luciferase and treated with
different nanoparticles, which was measured by bioluminescence in addition of luciferin. The
data were plotted as the percentage of bioluminescent intensity of surviving cells compared to
that of untreated controls. (C) Representative bioluminescent images of U87-TGL cells treated
with different kinds of particles at various concentrations.
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Figure 7.
Histological sections of liver, spleen, and kidney samples collected 7 days following injection
of PEG-HAuNS at a dose of 2.5×1011 particles/mouse. Sections were stained with H&E and
CD68 antibody for macrophage visualization. Bars, left=200 µm; middle=50 µm; right=25
µm. Arrows, mesangial cells.
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Table 1
The pharmacokinetic (PK) parameters of 111In-labeled PEGylated HAuNS in nude mice (n=7)
PK parameters Mean ± SD
T1/2α (h) 1.38 ± 0.38
T1/2β (h) 71.82 ± 30.46
AUC(0−∞) (ID%/mL·h) 281.59 ± 45.97
AUMC(0−∞) (ID%/mL·h2) 14193 ± 8136
MRT (h) 48.93 ± 22.78
CL (mL/h) 0.363 ± 0.058
Vss (mL) 17.3 ± 7.44
AUC = the area under the particle concentration-time curve; AUMC = the area under the first moment of the particle concentration-time curve; MRT
= mean residence time; CL = clearance; Vss = volume of distribution at steady-state. ID = injected dose.
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Table 2
The mouse serum level of biochemical variables at 7 days after intravenous treatment with PEG-HAuNS
(1×1012 per mouse)
Parameters Saline PEG-HAuNS
Creatinine (mg/dl) <0.20 <0.20
BUN (mg/dl) 25.4 ± 2.7 22.3 ± 4.9
AST (U/L) 105.6 ± 37.8 136.7 ± 72.5
ALT (U/L) 52.8 ± 19.3 54.4 ± 8.6
Alkaline phosphatase (U/L) 126.3 ± 34.5 115.4 ± 24.2
LDH (U/L) 363.3 ± 60.5 345.8 ± 74.5
Values are the means ± SD (ratio to control), n=7. There was no significant difference of the above parameters between PEG-HAuNS group and saline
control (p>0.05). BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, serum alanine aminotransferase; LDH, lactate dehydrogenase.
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